Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    COVID-19 | Degarelix
Previous Study | Return to List | Next Study

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04397718
Recruitment Status : Completed
First Posted : May 21, 2020
Last Update Posted : July 2, 2021
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development

Brief Summary:
The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Degarelix Other: Saline Phase 2

Detailed Description:

A novel coronavirus, now termed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), arose late in 2019. The first confirmed cases occurred in December in Wuhan, Hubei province, China. It now infects people on six continents, spreading person to person. The World Health Organization (WHO) classified it as a global pandemic on March 11, 2020. As of April 6, 2020, there are more than 1.2 million confirmed cases and more than 70,000 deaths attributed to this virus. Every person on Earth, as well as every United States Veteran, is at risk. This is the emergent public health threat of our time.

SARS-CoV-2 is a singled stranded RNA virus related to severe acute respiratory syndrome-related coronavirus (SARS-CoV-1). SARS-CoV-2 is thought to be transmissible largely by respiratory droplets or direct contact, but might also be transmitted through aerosolization. SARS-CoV-2 disease severity ranges from no to minimal symptoms, mildly symptomatic with cough and dyspnea, to severe respiratory distress with multi-organ failure requiring admission to an intensive care unit and emergent ventilator support. Although data are evolving, the severity of illness varies with age, co-existing comorbidities, and biological sex, with older age, people with pre-existing cardiovascular disease, and males manifesting greater disease severity.

A worldwide effort is in place to contain and suppress human-to-human transmission. These public-health strategies aim to slow the rate of spread and reduce the burden on critical care infrastructure. However, there is also a need effective therapeutics. Vaccine trials are underway but potential approvals are at least a year away. Development of new drugs de novo to treat SARS2-CoV-2 will likely take even longer. Thus, the most expedient therapeutic strategy to confront this pandemic will repurpose existing FDA-approved therapeutics. One potential strategy targets viral components directly, using existing antivirals and anti-infectives currently used for other diseases. Such efforts include trials of hydroxychloroquine, remdesivir, and ribavirin. Another strategy involves targeting the human proteins, rather than viral proteins, required for SARS CoV-2 entry and replication.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix
Actual Study Start Date : July 6, 2020
Actual Primary Completion Date : June 8, 2021
Actual Study Completion Date : June 8, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Degarelix

Arm Intervention/treatment
Placebo Comparator: Placebo + BSC
No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
Other: Saline
09% Saline

Experimental: Degarelix + BSC
Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
Drug: Degarelix
Degarelix is an FDA-approved drug for prostate cancer




Primary Outcome Measures :
  1. A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization. [ Time Frame: 15 days ]
    Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.


Secondary Outcome Measures :
  1. Time to clinical improvement [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC reduces time to clinical improvement as defined by a decline of 2 categories or more from the baseline on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients or hospital discharge whichever comes first.

  2. Inpatient mortality [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC reduces inpatient mortality.

  3. Duration of hospitalization [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of hospitalization.

  4. Duration of intubation for mechanical ventilation. [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of intubation for mechanical ventilation.

  5. Time to normalization of temperature. [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC reduces the time to normalization of temperature (T < 37.5 for 48 hours)

  6. Maximum severity of COVID19 illness. [ Time Frame: Through study completion/discharge (an average of 30 days with a maximum of 4 months) ]
    Determine if degarelix + BSC as compared to placebo + BSC reduces the maximum severity of COVID-19 illness based on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients. Score range 1-7, higher scores equals worse outcome.

  7. A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization. [ Time Frame: 30 days ]
    Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male Veterans admitted to a VA hospital.
  • Age > 18
  • Hospitalized on an acute care ward with a diagnosis of COVID-19 contributing to hospitalization.
  • Positive RT-PCR assay for SARS-CoV-2 on a nasopharyngeal swab sample.
  • Severity of illness of level 3, 4 or 5 on the influenza severity scale (see Appendix A) at the time of randomization.
  • The subject (or legally acceptable representative if applicable) must provide written informed consent for the trial.

Exclusion Criteria:

  • History of severe hypersensitivity to degarelix or any component of their respective formulation.
  • History of congenital long QT syndrome or known history of prolonged QT interval corrected by the Fridericia correction formula (QTcF) > 500 msec on electrocardiogram performed at screening.
  • Planned discharge within 24 hours of treatment initiation.
  • Subject is planning to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
  • Ongoing usage of a Class IA or Class III antiarrhythmic agent. At least 5 half lives must elapse since any prior use of a Class IA or III antiarrhythmic agent prior to administration of study drug.

    --Baseline electrolyte abnormalities of Grade 3 or higher (based on CTCAE v5.0 criteria). Patients may be included if baseline electrolyte abnormalities are corrected to Grade 2 or lower prior to study drug administration.

  • Myocardial infarction in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease.
  • Enrollment in another investigational study within 30 days of Day 1.
  • Known psychiatric or substance abuse disorder that would interfere with the requirements of the trial.
  • Child-Pugh Class C liver disease.
  • Use of any of the following hormonal agents within Day 1 of treatment:

    1. Androgen receptor antagonists or agonists within 4 weeks,
    2. Ketoconazole or abiraterone acetate within 2 weeks,
    3. Estrogens or progestins within 2 weeks,
    4. Herbal products that contain hormonally active agents within 2 weeks.
  • Unwilling or unable to comply with the study protocol.
  • Any condition, which in the opinion of the investigator, would preclude participation in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04397718


Locations
Layout table for location information
United States, Arizona
Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona, United States, 85012
United States, Arkansas
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
Little Rock, Arkansas, United States, 72205-5484
United States, California
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California, United States, 90822
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Los Angeles, California, United States, 90073
United States, Florida
Miami VA Healthcare System, Miami, FL
Miami, Florida, United States, 33125
United States, Missouri
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
Saint Louis, Missouri, United States, 63106
United States, New York
Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY
Brooklyn, New York, United States, 11209
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
New York, New York, United States, 10010
United States, Pennsylvania
Philadelphia MultiService Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States, 19106
United States, South Carolina
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina, United States, 29401-5799
United States, Tennessee
Memphis VA Medical Center, Memphis, TN
Memphis, Tennessee, United States, 38104
United States, Texas
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Dallas, Texas, United States, 75216
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States, 77030
United States, Washington
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States, 98108
Sponsors and Collaborators
VA Office of Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Matthew B. Rettig, MD VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT04397718    
Other Study ID Numbers: COVID19-8900-15
First Posted: May 21, 2020    Key Record Dates
Last Update Posted: July 2, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases